Skip to search formSkip to main contentSkip to account menu

NUDCD1 gene

Known as: NUDCD1, NUDC DOMAIN-CONTAINING PROTEIN 1, NudC domain containing 1 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Genes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Aberrant expression of long non-coding RNAs (lncRNAs) is involved in brain glioma development
Introduction Aberrant expression of long non-coding RNAs (lncRNAs) has been implicated in various diseases, including cancer… 
2018
2018
NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and… 
2014
2014
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Ovarian cancer-associated antigen 66 (OVA66), also known as CML66 (GenBank Accession No. AF283301), was first identified in an… 
2011
2011
Structural features and chaperone activity of the NudC protein family.
2010
2010
Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion
Purpose: The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. Experimental… 
2008
2008
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
2008
2008
Identification of an epitope derived from CML66, a novel tumor‐associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen‐A*2402‐restricted cytotoxic T lymphocytes
CML66 is a newly identified differentiation antigen that is expressed broadly in human leukemia and solid tumors, but its… 
Highly Cited
2005
Highly Cited
2005
Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells
Purpose: Donor lymphocyte infusion (DLI) reliably induces durable remission in 75% to 80% of patients with relapsed chronic… 
2004
2004
A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L1
This report describes the difference in the epitope generation of two isoforms of self-tumor Ag CML66 and the regulation… 
Highly Cited
2001
Highly Cited
2001
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
This report describes a tumor-associated antigen, termed CML66, initially cloned from a chronic myelogenous leukemia (CML) cDNA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)